StreetInsider.com News Articles

Form 8-K Jaguar Health, Inc. For: Jun 17

Thu, 18 Jun 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260618/26667270.html

Form 8-K Jaguar Health, Inc. For: Jun 17

Thu, 18 Jun 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260618/26667270.html

Red Light Holland reports preclinical coca extract results for post-GLP-1 weight management

Thu, 18 Jun 2026 09:03:15 -0400

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) announced that Magdalena Biosciences, a joint venture held through its wholly owned subsidiary Filament Health Corp., has reported positive results from a preclinical study involving a coca leaf extract as a potential weight management therapy following GLP-1 drug cessation.

The 20-day study, conducted in Alberta, Canada, in collaboration with the Borgland Lab at the University of Calgary, found that a novel extract derived from coca leaves prevented weight gain in mice placed on a high-fat diet, without reducing food intake or increasing physical activity. Stephanie Borgland, PhD, served as principal investigator.

Magdalena

Red Light Holland reports preclinical coca extract results for post-GLP-1 weight management

Thu, 18 Jun 2026 09:03:15 -0400

Magdalena

Magdalena Biosciences coca extract prevents weight gain in mice

Thu, 18 Jun 2026 09:01:13 -0400

Magdalena Biosciences, a joint venture between Jaguar Health, Inc. (NASDAQ: JAGX) and Filament Health Corp., has reported positive results from a 20-day preclinical study of a coca leaf extract conducted at the University of Calgary in Alberta, Canada.

The study found that a novel extract derived from coca plant leaves prevented weight gain in mice on a high-fat diet, without reducing food intake or increasing physical activity. The extract is Magdalena's prescription drug candidate intended for post-GLP-1 weight loss management and is being developed under the U.S. Food and Drug Administration's Botanical Guidance framework.

Weight regain is common after patients stop taking

Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filam

Thu, 18 Jun 2026 09:01:00 -0400

Whole leaf coca extract under evaluation is Magdalena's drug candidate for post GLP-1 weight loss management

Toronto, Ontario--(Newsfile Corp. - June 18, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived drug development. Through the Filament acquisition, the Company also holds Filament's interest in Magdalena Biosciences, Inc. ("Magdalena"), a

Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filam

Thu, 18 Jun 2026 09:01:00 -0400

Whole leaf coca extract under evaluation is Magdalena's drug candidate for post GLP-1 weight loss management

Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filam

Thu, 18 Jun 2026 09:01:00 -0400

Whole leaf coca extract under evaluation is Magdalena's drug candidate for post GLP-1 weight loss management

Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filam

Thu, 18 Jun 2026 09:01:00 -0400

Whole leaf coca extract under evaluation is Magdalena's drug candidate for post GLP-1 weight loss management

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention

Thu, 18 Jun 2026 09:00:00 -0400

Whole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss management

SAN FRANCISCO, CA / ACCESS Newswire / June 18, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the results of a preclinical study initiated by Magdalena Biosciences ("Magdalena"), a US-based joint venture formed by Jaguar and Canada-based Filament Health Corp. ("Filament"), demonstrate that a novel extract derived from leaves of the coca plant prevented weight gain in mice submitted to a high fat diet without reducing food

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention

Thu, 18 Jun 2026 09:00:00 -0400

Whole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss management

Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases

Fri, 12 Jun 2026 09:00:00 -0400

Click here to register for event

To access the replay of the June 10, 2026 presentation by Lisa Conte, Jaguar's founder, president & CEO, at the Emerging Growth Conference, click here

Reminder: Two crofelemer presentations in pediatric intestinal failure patients with microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) to be conducted at June 24-27, 2026 Annual European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) Meeting

SAN FRANCISCO, CA / ACCESS Newswire / June 12, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today

Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases

Fri, 12 Jun 2026 09:00:00 -0400

Click here to register for event

To access the replay of the June 10, 2026 presentation by Lisa Conte, Jaguar's founder, president & CEO, at the Emerging Growth Conference, click here

SAN FRANCISCO, CA / ACCESS Newswire / June 12, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today

Form 8-K Jaguar Health, Inc. For: Jun 08

Thu, 11 Jun 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260611/26633388.html

Form 8-K Jaguar Health, Inc. For: Jun 08

Thu, 11 Jun 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260611/26633388.html

Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream